跳至主要内容
临床试验/NCT02437760
NCT02437760Unknown不适用

Determination of the Prognostic and Predictive Value of the Cancer Antigen-125 (CA-125) Marker in Lung Cancer Monitoring

E-DA Hospital1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2015年2月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
200
试验地点
1
主要终点
The diagnostic Value of the cancer antigen-125 in lung cancer

研究概览

简要总结

The tumor associated CA-125antigen for diagnosis and follow-up of ovarian cancer was well defined. Increased serum CA125 level may have many diagnoses other than ovarian cancer, including breast, colorectal and lung cancer. 80% lung cancer patients were diagnosed at advanced stage. Malignant pleural effusion secondary to lung cancer represented the condition of cancer cell involved pleura.

The CA-125 level may reflect the extent of tumor involved in pleura (tumor burden), it could be correlated with the prognosis. This study was performed to examine the properties of CA-125 by measuring pleural and blood CA-125 levels in lung cancer with or without malignant pleural effusion; meanwhile to examine whether the rate of decline in CA 125 during primary therapy as a surrogate indicator for survival.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically proved lung cancer

排除标准

  • History of other cancers within the past 5 years
  • Pregnancy or breast milk feeding
  • TB pleuritis and peritonitis

结局指标

主要结局

The diagnostic Value of the cancer antigen-125 in lung cancer

时间窗: 12months

1. Comparison of CA-125 level in serum between lung cancer patients with or without malignant pleural effusion 2. The correlation between serum and pleural effusion CA-125 level

次要结局

  • The prognostic value of the cancer antigen-125 in lung cancer(24 months)

研究者

发起方
E-DA Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验